CTOR

Citius Oncology
CTOR

Overview Fund Trends Analyst Outlook Journalist POV
1.79 USD
+0.07
4.07%
At close Updated Oct 16, 4:00 PM EDT
Pre-market
After hours
1.76
--0.03
1.68%
1 day
4.07%
5 days
-3.24%
1 month
-3.76%
3 months
14.01%
6 months
177.09%
Year to date
50.42%
1 year
65.74%
5 years
-82.26%
10 years
-82.26%
 

About: Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Healthcare Drug Manufacturers - Specialty & Generic
0
Funds holding %
of 7,495 funds
Explore Fund Trends
0
Analysts bullish %
of 1 analysts
See Analyst Outlook
–
Positive news %
of articles
Check Journalist POV
Price charts implemented using Lightweight Charts™